A novel mouse model of a highly lethal form of acute myeloid leukemia (AML) offers a new tool for scientists working to better understand this disease and research new therapeutic targets. Scientists ...

SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- A demonstrated 100% concordance between biomarker-guided predictions from pre-treatment patient samples and clinical outcomes validates Yatiri Bio’s ...

A highly aggressive common form of leukaemia which is activated by mutations in signalling molecules is maintained by a web of regulatory proteins downstream of these signals. New research published ...

Scientists at the University of Glasgow developed a bioengineered bone marrow (BM) model that helped them to evaluate potential use of a combined CRISPR-CAR T cell therapy in the treatment of acute ...

AUTX-703, a first-in-class oral KAT2A/B degrader, received FDA fast track designation for relapsed or refractory AML treatment. Promising preclinical data showed AUTX-703's effective KAT2A/B ...

Data demonstrate dose dependent survival advantage with AUTX-703 in primary patient-derived orthotopic AML model IND submissions on track for late 2024 NEWTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- ...

Sellas will present new data on its CDK9 inhibitor SLS009 at the American Association for Cancer Research (AACR) meeting on April 21. ・Preclinical findings showed SLS009 triggered leukemia cell death ...

Moleculin Biotech, Inc. (NASDAQ:MBRX) shares are trading higher on Wednesday after the company announced the online publication of preclinical data for its Annamycin Venetoclax Resistant AML model.